Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2022-08-16 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Celltrion Pharm, Inc. for the period ending June 30, 2022. It contains detailed financial statements, business operations, capital structure, and management discussions, which are characteristic of an interim financial report. It is not an announcement of a report, but the report itself, and it contains substantive financial data. H1 2022
2022-08-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS). This type of filing is a mandatory disclosure by company insiders (executives/directors) regarding their personal shareholdings and changes therein, which corresponds to the 'Director's Dealing' category.
2022-08-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a standard disclosure for insider transactions or changes in share ownership by company directors and executives. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2022-08-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of an executive (Yang Ji-seok) at Celltrion Pharm. This is a standard regulatory filing for insider trading/shareholding reporting, which corresponds to the 'Director's Dealing' category.
2022-08-04 Korean
특수관계인으로부터받은담보
Capital/Financing Update Classification · 95% confidence The document is a regulatory disclosure regarding a collateral transaction between related parties (Celltrion Pharm and Celltrion Holdings). It details the terms of the collateral, the board approval date, and the purpose of the transaction. Since it is a specific regulatory disclosure of a corporate transaction that does not fit into the other categories like earnings, dividends, or share repurchases, it is classified as a general regulatory filing.
2022-06-28 Korean
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Major Shareholding Notification Classification · 100% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Celltrion Pharm. This is a mandatory regulatory filing in South Korea required by the Fair Trade Commission for large business groups to disclose corporate structure, financial status, board composition, shareholding, and internal transactions. It does not fit into financial reporting categories like 10-K or IR, nor is it an announcement of a report (RPA). It is a specific regulatory disclosure document, which falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous regulatory filings.
2022-05-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.